company background image
SGEN logo

Seagen NasdaqGS:SGEN Stock Report

Last Price

US$228.74

Market Cap

US$43.2b

7D

4.5%

1Y

76.5%

Updated

15 Dec, 2023

Data

Company Financials +

SGEN Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

SGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for SGEN from our risk checks.

Seagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share PriceUS$228.74
52 Week HighUS$228.96
52 Week LowUS$123.77
Beta0.32
1 Month Change7.86%
3 Month Change9.76%
1 Year Change76.48%
3 Year Change13.72%
5 Year Change336.44%
Change since IPO2,672.61%

Recent News & Updates

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Dec 12
Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Recent updates

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Dec 12
Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Apr 17
A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Mar 20
Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Dec 09
An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Oct 14
Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Seagen: A Stellar Portfolio Anchor

Oct 04

Seagen in licensing deal with Lava Therapeutics for cancer candidate

Sep 26

Seagen ticks lower as management suggests it could look at acquisitions

Sep 14

Merck's talks with Seagen said to hit obstacle over price - report

Aug 26

Seagen falls as arbitrator rules in favor of Daiichi Sankyo

Aug 12

Shareholder Returns

SGENUS BiotechsUS Market
7D4.5%4.2%1.8%
1Y76.5%11.1%25.6%

Return vs Industry: SGEN exceeded the US Biotechs industry which returned -0.9% over the past year.

Return vs Market: SGEN exceeded the US Market which returned 20.8% over the past year.

Price Volatility

Is SGEN's price volatile compared to industry and market?
SGEN volatility
SGEN Average Weekly Movement1.8%
Biotechs Industry Average Movement11.8%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: SGEN has not had significant price volatility in the past 3 months.

Volatility Over Time: SGEN's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19973,256David Epsteinhttps://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
SGEN fundamental statistics
Market capUS$43.15b
Earnings (TTM)-US$750.22m
Revenue (TTM)US$2.30b

18.8x

P/S Ratio

-57.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SGEN income statement (TTM)
RevenueUS$2.30b
Cost of RevenueUS$2.13b
Gross ProfitUS$171.59m
Other ExpensesUS$921.81m
Earnings-US$750.22m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.98
Gross Margin7.46%
Net Profit Margin-32.61%
Debt/Equity Ratio0%

How did SGEN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.